TipRanks
Go Ultimate55% OFF

Scientific Industries (SCND) AI Stock Analysis

18 Followers
SCND

Scientific Industries

(Other OTC:SCND)

Select Model
Rating:49Neutral
Price Target:$0.60â–¼(-0.50% Downside)
Action:reiterated
Date:10/02/26

The overall score is constrained by weak and contracting fundamentals, including sharp revenue declines, compressed margins, and rising cash burn, despite low leverage, while a mildly constructive technical setup and recent leadership-stability initiatives provide limited offset to valuation risks tied to continued losses.

Positive Factors
Low leverage and balance-sheet resilienceLow leverage gives Scientific Industries greater financial flexibility than a highly indebted business and reduces exposure to refinancing pressure. Its sizable equity base provides some resilience while management works to restore profitability, although it does not eliminate the effects of ongoing losses and cash use.
Negative Factors
Sharp revenue deteriorationA roughly 44% annual revenue decline indicates substantial deterioration in demand, sales execution, or business mix rather than steady expansion. If not reversed, the smaller revenue base can reduce operating leverage, constrain investment capacity, and make a return to sustainable profitability more difficult.

Scientific Industries (SCND) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%40%50%SCND-2.42%SPY+13.75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$7.75M
Dividend Yield
―
Average Volume (3M)
6,264
Price to Earnings (P/E)
-13.0
Beta (1Y)
0.31
Revenue Growth
-44.48%
EPS Growth
90.56%
Country
US
Employees
55
Sector
Technology
Sector Strength
61
Industry
Hardware, Equipment & Parts

Scientific Industries Business Overview & Revenue Model

Company Description

Scientific Industries, Inc. operates as a global enterprise specializing in the development, production, and distribution of a comprehensive range of benchtop laboratory instrumentation and advanced bioprocessing systems. Their product line features...

Scientific Industries Earnings Call Summary

Earnings Call Date:Nov 14, 2024(Q3-2024)|% Change Since:-19.23%|Next Earnings Date:Nov 13, 2019
Earnings Call SentimentPositive

The earnings call highlighted significant growth in the VIVID pill counter business and successful cost-cutting initiatives, alongside promising developments and strategic partnerships in the bioprocessing segment. However, challenges in the European market remain a concern.

Positive Updates

VIVID Pill Counter Business Growth
VIVID sales in the third quarter were up 50% compared to the second quarter of this year and 12% compared to the same quarter last year. The development of a new VIVID workstation is expected to be a game-changer in the market.

Negative Updates

Challenging Bioprocessing Market
The bioprocessing segment faced a challenging environment with budget constraints impacting customers, particularly in Europe, leading to postponed equipment investments.

Company Guidance

During the third quarter of 2024, Scientific Industries demonstrated significant progress in its strategic transformation into a life sciences tool business with notable growth in sales, margins, and recurring revenue. The legacy Genie business experienced a recovery, generating positive cash flow that supports investments in the VIVID pill counter business, which saw a 50% increase in sales compared to the previous quarter and 12% year-over-year growth. The company is excited about the upcoming launch of the VIVID workstation, a new all-in-one pill counter and pharmacy management system. In the bioprocessing segment, sales increased by 12% compared to the previous year, with a remarkable 61% year-over-year growth in the U.S. market. Efforts to improve cost efficiency resulted in a reduction of operating expenses by over $1 million, or 22%, compared to the previous year. The company also reported a positive EBITDA margin of 14% for its U.S. entity in September, marking a significant milestone. Scientific Industries continues to invest in R&D and commercial activities, with a growing commercial pipeline and the successful launch of the DOTS platform, reflecting its potential to deliver long-term shareholder value.

Scientific Industries Financial Statement Overview

Summary

Revenue has declined sharply, margins have compressed, and operating cash burn has worsened, leaving the company in a distressed but low-leverage financial position.

Income Statement

12Very Negative

Balance Sheet

45Neutral

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Jun 2022Sep 2021
Income Statement
Total Revenue5.73M5.05M10.71M11.11M10.48M9.78M
Gross Profit1.67M1.30M4.73M5.10M4.64M4.98M
EBITDA-6.79M-7.89M-5.89M-8.51M-7.41M-4.46M
Net Income-742.30K-1.22M-6.45M-9.09M-8.15M-3.11M
Balance Sheet
Total Assets10.11M12.61M11.56M16.73M18.07M29.01M
Cash, Cash Equivalents and Short-Term Investments4.55M6.66M2.57M5.72M6.20M13.42M
Total Debt790.70K966.70K1.00M1.33M1.43M1.49M
Total Liabilities2.03M1.94M2.44M2.85M3.28M2.78M
Stockholders Equity8.07M10.66M9.12M13.89M14.79M26.22M
Cash Flow
Free Cash Flow-6.60M-8.21M-3.78M-6.29M-6.20M-3.56M
Operating Cash Flow-6.95M-8.15M-3.68M-6.16M-5.70M-3.30M
Investing Cash Flow3.99M3.83M2.87M-735.10K3.61M-10.88M
Financing Cash Flow500.00K1.95M645.70K5.75M2.31M16.31M

Scientific Industries Technical Analysis

Technical Analysis SentimentNegative
Last Price0.60

Price Trends

50DMA0.75Negative
100DMA0.69Negative
200DMA0.69Negative

Market Momentum

MACD-0.03Positive
RSI17.18Positive
STOCH14.15Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCND, the sentiment is Negative. The current price of 0.60 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.75, and below the 200-day MA of 0.69, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 17.18 is Positive, neither overbought nor oversold. The STOCH value of 14.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCND.

Scientific Industries Risk Analysis

Scientific Industries disclosed 12 risk factors in its most recent earnings report. Scientific Industries reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Scientific Industries Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

SCND against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
SCNDSCND49Neutral$7.22M-13.00-7.37%―-44.48%90.56%
ELTKELTK46Neutral$41.00M-6.73-13.57%―-2.20%-297.64%
SOBRSOBR39Underperform$240.27K-0.04-310.87%―17.67%92.17%
SVRESVRE39Underperform$341.46M-0.03-329.57%―-68.00%97.75%

* Technology Sector Average

Performance Comparison

-50%0%SCNDELTKIMTESOBROSTSVREDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SCND and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SCNDScientific Industries 0.60-0.03-3.97%
ELTKEltek6.13-5.07-45.27%
IMTEIntegrated Media Technology0.35-0.52-59.68%
SOBRSobr Safe, Inc.0.04-2.79-98.48%
OSTOstin Technology Group Co., Ltd.1.700.000.00%
SVRESaverOne 2014 Ltd. ADR0.58-12.86-95.68%

Scientific Industries Corporate Events

Business Operations and StrategyExecutive/Board Changes

Scientific Industries Strengthens Executive Leadership Through New Agreements

Positive
Oct 2, 2026

On October 1, 2026, Scientific Industries entered into a new employment agreement with Chief Financial Officer Zachary Rovinsky, securing his role through September 30, 2028 with an annual salary of $210,000, a bonus opportunity up to 10%, and schedu...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 02, 2026